Elsevier

The Lancet

Volume 351, Issue 9117, 6 June 1998, Pages 1701-1702
The Lancet

Research Letters
Prope tolerance, perioperative campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients

https://doi.org/10.1016/S0140-6736(05)77739-4Get rights and content

References (5)

  • RY Calne et al.

    Induction of Immunological tolerance by porcine liver allografts

    Nature

    (1969)
  • V Sriwatanawongsa et al.

    The essential roles of parenchymal tissues and passenger leukocytes in the tolerance induced by liver grafting in rats

    Nat Med

    (1995)
There are more references available in the full text version of this article.

Cited by (403)

  • Alemtuzumab in renal transplantation. Reviews of literature and usage in the United Kingdom

    2022, Transplantation Reviews
    Citation Excerpt :

    Roy Calne and colleagues carried out the first non-randomised trial of Campath 1H in kidney transplant recipients in 1997 in 13 kidney transplant recipients. The study results demonstrated both a good safety profile and good graft survival [22]. In 2001 the FDA and the European Medicines Agency approved the use of alemtuzumab to treat B-cell chronic lymphocytic leukaemia, and in 2013/2014, it received approval to be used in the treatment of multiple sclerosis [33].

  • Solid Organ Transplantation: Rejection, Immunosuppression, and Tolerance

    2022, Clinical Immunology: Principles and Practice, Sixth Edition
  • Immunosuppression in Liver Transplantation

    2022, Comprehensive Pharmacology
  • Perioperative Management of Renal Failure and Renal Transplant

    2021, Perioperative Medicine: Managing for Outcome, Second Edition
  • Concepts and Challenges in Organ Transplantation

    2019, Clinical Immunology: Principles and Practice
View all citing articles on Scopus
View full text